XNAS · Medical Care Facilities
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$185.09+1.64%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
44/100
Weak
Score components
TickerWhale View
Ensign Group scores 44 out of 100 overall, which we rate weak. Risk is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Risk
What to watch
- Quality & growth
- Valuation
- Sentiment Signal
Quality & growth
30%27Weak
- Revenue growth 18.9%
- EPS growth 15.8%
Valuation
25%37Weak
- P/E 29.1
- EV/Sales 2.0
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#113 / 139sector rank by TickerWhale Score
TickerWhale Score 44 vs sector average 54.6 (-10.6)
Revenue growth (industry)Top 18%
Gross margin (industry)Top 83%
Return on equity (industry)Top 78%
P/E (industry)Pricier than 73%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
59/100Positive vs universe
Ranks 59th of 100 covered names on our technical composite — the composite itself scores 62/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
4 buy · 0 sell · 4 neutral of 8 votes
TickerWhale rates ENSG's technical setup middling — 59th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+1.8%
- vs 50-day+5.4%
Momentum
Mixed
- RSI (14)57 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength16· weak trend
- MACD (12,26,9)buy(histogram 0.445)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 0 sell · 4 neutral.
Result — 4 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)29.1
- P/S (TTM)2.0
- P/B4.5
- EV/EBITDA—
- EV/Sales2.0
- PEG1.84
Profitability & returns
- Gross margin22.8%
- Net margin6.9%
- ROE15.8%
- Debt/Equity0.06
Growth
- Revenue growth (YoY)18.9%
- EPS growth (YoY)15.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $11.0B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ENSGCurrentEnsign Group | 44 | 62 | 29.1 | — | 4.5 | 2.0 | $185.09 | +1.64% | +18.9% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.